Angela W. Dymond

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial

Myung‐Ju Ahn, Byoung Chul Cho, Xiaoling Ou et al. · Journal of Thoracic Oncology · 2022 · 85 citations · Full text

Medicine, Oncology, Pharmacology +13

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Aurelius Omlin, Robert J. Jones, Ruud van der Noll et al. · Investigational New Drugs · 2015 · 48 citations

Medicine, Oncology, Pharmacology +16

Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects

Angela W. Dymond, Colin Howes, Christine Pattison et al. · Clinical Therapeutics · 2016 · 33 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

The functional observational battery and modified Irwin test as global neurobehavioral assessments in the rat: Pharmacological validation data and a comparison of methods

William S. Redfern, Angela W. Dymond, Isobel Strang et al. · Journal of Pharmacological and Toxicological Methods · 2019 · 32 citations

Medicine, Neuroscience, Pharmacology +11

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

Angela W. Dymond, Karen So, Paul Martin et al. · European Journal of Clinical Pharmacology · 2016 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15